Twist Bioscience (NASDAQ:TWST) Shares Gap Up - Time to Buy?

Key Points

• Twist Bioscience's stock price experienced a gap up, opening at $33.32 after closing at $31.89, with significant trading volume of 324,932 shares.
• Analysts generally hold a positive outlook, with nine buy ratings and a consensus price target of $48.50, despite recent adjustments lowering some estimates.
• The company reported a quarterly revenue of $96.06 million, surpassing expectations, and achieved an earnings per share of ($0.47), exceeding the consensus estimate of ($0.54).

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $31.89, but opened at $33.32. Twist Bioscience shares last traded at $31.77, with a volume of 324,932 shares changing hands.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TWST shares. Cowen reissued a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research report on Wednesday. Evercore ISI lowered their price target on Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating for the company in a research report on Tuesday. Finally, Barclays lowered their price target on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a research report on Thursday, October 2nd. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Twist Bioscience presently has an average rating of "Moderate Buy" and an average price target of $48.50.

Twist Bioscience Stock Performance

The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The company has a 50 day moving average of $27.68 and a 200 day moving average of $32.75. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -21.75 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The business had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Activity

In other Twist Bioscience news, CAO Robert F. Werner sold 2,041 shares of the company's stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $32.19, for a total transaction of $65,699.79. Following the sale, the chief accounting officer owned 46,413 shares in the company, valued at $1,494,034.47. This represents a 4.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Dennis Cho sold 3,876 shares of the company's stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $124,768.44. Following the sale, the insider owned 98,710 shares in the company, valued at $3,177,474.90. The trade was a 3.78% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 58,851 shares of company stock valued at $1,859,894 over the last three months. Company insiders own 3.01% of the company's stock.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC increased its position in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after acquiring an additional 303 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Twist Bioscience by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after purchasing an additional 302 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in Twist Bioscience during the 2nd quarter valued at $97,000. Bayforest Capital Ltd boosted its stake in Twist Bioscience by 49.3% during the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock valued at $191,000 after purchasing an additional 1,604 shares in the last quarter. Finally, Pallas Capital Advisors LLC bought a new position in Twist Bioscience during the 1st quarter valued at $201,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.